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Abstract
Background: Cancer of unknown primary (CUP) is a distinct clinicopathological 
entity with poor prognosis, frequently resistant to chemotherapy. Comprehensive 
genomic profiling (CGP) by next- generation sequencing potentially identifies 
novel treatment options for CUP patients. The objective of this study was to deter-
mine incidence and survival trends and to discuss the value of CGP in CUP 
patients.
Methods: Age- standardized incidence rates (ASR) per 100 000 were calculated for 
2935 CUP patients from 1981 to 2014 using cancer registry data of the canton of 
Zurich, Switzerland. Kaplan–Meier survival curves were estimated for sex, age, and 
histological groups. Cox proportional hazards regression models were used to esti-
mate adjusted hazard ratios (HR). A literature review was conducted to assess the 
current use of CGP in CUP patients.
Results: ASR of CUP increased from 10.3 to 17.6 between 1981 and 1997 and de-
creased to 5.8/100 000 in 2014. Mean overall survival remained stable. Mortality 
was significantly lower for patients with squamous cell carcinoma (HR 0.48 [95% 
CI, 0.41- 0.57]) and neuroendocrine carcinoma (0.75 [0.63- 0.88]) and higher for un-
classified neoplasms (1.25 [1.13- 1.66]) compared to adenocarcinomas. The literature 
review identified 10 studies using CGP of CUP tissue. Clinically relevant mutations 
were identified in up to 85% of CUP patients, of which 13%- 64% may benefit from 
currently available drugs.
Conclusions: CUP incidence decreased probably due to improved diagnostics, but 
mortality did not improve over the last 34 years. CGP testing may help to identify 
molecular signatures in CUP patients and enable targeted treatment.
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cancer diagnostics, cancer of unknown primary, comprehensive genomic profiling, epidemiology, 
molecular profiling, next-generation sequencing
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1 |  INTRODUCTION
Cancer of unknown primary (CUP) is a heterogeneous group 
of aggressive metastatic tumors for which a standardized di-
agnostic workup fails to identify the site of origin at the time 
of presentation.1 It accounts for 2%- 5% of all new cancer diag-
noses.2-5 The inability to identify the tissue of origin in CUP 
patients is an immense clinical challenge, as the primary site 
of cancer influences treatment choices, outcome, and prog-
nosis.6 Therefore, treatment options are limited in CUP pa-
tients and research efforts lag behind that of other solid tumor 
types.7 Conventional chemotherapy regimens, such as taxane 
based, platinum based, or combination of both, have not been 
able to substantially increase overall survival of unfavorable 
prognostic CUP groups.8 Therefore, these patients may pres-
ent ideal candidates for personalized and targeted therapies.
The diagnostic workup of CUP includes the extensive 
use of diagnostic technologies, including modern imaging 
and endoscopy technologies on the one hand and detailed 
histopathological, immunohistochemical, molecular, and 
serum tumor marker investigations on the other. In gen-
eral, tissue- based diagnostics are considered a relatively 
cost- efficient tool with substantial impact on diagnostic and 
therapeutic decisions.9 Recently, gene expression assays and 
next- generation sequencing (NGS) have been proposed to de-
termine the site of origin and potential treatment options in 
CUP.10-13 Comprehensive Genomic Profiling (CGP) by NGS 
is a novel powerful tool to identify tumor- specific genetic 
changes, which can be targeted with genotype- directed treat-
ment.14 For example, the majority (83%) of advanced breast 
and head and neck cancers, as well as melanoma patients har-
bored potentially actionable genetic alterations identified by 
NGS.14
Currently, CGP is introduced in many US and European 
laboratories. Due to poor prognosis and limited therapeutic 
options, CGP is a useful diagnostic approach especially in 
CUP patients. In this study, incidence and survival trends of 
CUPs were investigated using cancer registry data of the can-
ton or Zurich. Furthermore, the current knowledge on CGP 
testing for the management of CUP patients was assessed by 
a literature review.
2 |  MATERIALS AND METHODS
2.1 | Data source and study population
Cancer Registry of Zurich and Zug in Switzerland provided 
population data of the canton of Zurich for the period of 
1981- 2014. This region is home to 18% of the Swiss popu-
lation.15 Recent population- based epidemiological stud-
ies consider different ranges of diagnostic codes for CUP 
patients from ICD- O- 3 C80.9 only16,17 to ranges ICD- O- 3 
C76/C77 to C80.94,18,19 or even broader.19,20 To avoid 
inclusion of patients with identifiable cancers that have 
been not accurately documented, only patients classified 
with a tumor of “unknown primary site” ICD- 10 code C80 
were considered for this study, leading to a total number 
of 2935 patients. Further, 175 (5.9%) cases diagnosed on 
death certificate only and 91 (3.1%) cases diagnosed only 
by autopsy were excluded to analyze the time of survival 
after the initial diagnosis. This resulted in 2669 patients, 
which were included in the analysis. These patients were 
followed- up until death or were censored on 31 December 
2014, whichever came first. Patients were grouped into 
four histological and age subgroups. The histological 
groups were categorized as suggested by Fizazi et al1 based 
on the ICD- O 3 morphological codes: adenocarcinomas 
(M- 814, M- 820, M- 821, M- 826, M- 831, M- 836, M- 843, 
M- 848, M- 849, M- 857, M- 898), squamous cell carcinomas 
(M- 805, M- 807, M- 812, M- 856), neuroendocrine carcino-
mas (M- 804, M- 824), unspecified carcinomas (NOS), incl. 
undifferentiated carcinomas (M- 801, M- 802, M- 803, M- 
823), and unclassified neoplasms/tumors (M- 800). The age 
groups were formed according to the age at diagnosis: <60, 
60- 69, 70- 79, and ≥80 years.
2.2 | Statistical analysis
Age- standardized incidence rates (ASR) were calculated 
as cases per 100 000 person years using the standardized 
European population.21 Kaplan–Meier survival curves were 
estimated for sex, age, and histological groups. Multivariate 
Cox proportional hazards models were used to estimate haz-
ard ratios (HR) and 95% confidence intervals (CI) for sex, 
age groups, and histological groups. As the incidence year 
did not have an influence on overall survival, it was not in-
cluded in the final analysis. All statistical analyses were per-
formed using R Version 3.4.0.
2.3 | Literature review on CGP and 
expression profiling
A literature review was conducted to assess the current view 
and recent scientific advances with regard to CGP and expres-
sion profiling for CUP patients. The search was conducted in 
PubMed on 31 May 2018 with following key words: “cancer 
of unknown primary (CUP) and genetic/genomic profiling,” 
“cancer of unknown primary (CUP) and next- generation se-
quencing,” “cancer of unknown primary (CUP) and sequenc-
ing,” “cancer of unknown primary (CUP) and molecular 
profiling,” and “cancer of unknown primary (CUP) and gene 
expression profiling.” Peer- reviewed publications in English 
language that documented new insights about gene panels 
testing for CUP patients were considered. Relevant refer-
ences in the identified publications were also consulted.
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3 |  RESULTS
3.1 | Patient population, trends in incidence, 
age at diagnosis and survival
There were 2935 patients registered with CUP in the can-
ton of Zurich between 1981 and 2014, of which 47.0% were 
male and 52.0% were female. Mean age at diagnosis was 
72.9 years (SD ±12.7; median = 75.0). The largest histologi-
cal group was adenocarcinomas (42.3%), followed by unclas-
sified neoplasms/tumors (28.1%) and unspecified carcinomas 
(NOS), incl. undifferentiated carcinoma (16.6%). Squamous 
cell carcinomas and neuroendocrine carcinomas accounted 
for <7% of the cases each (Table 1). CUPs accounted for 
0.9%- 2.6% of all new cancer diagnoses with a peak in 1997 
and with a decrease to 1.1% in 2014 (Figure S1). Similarly, 
there was an increasing trend of ASR from 10.3/100 000 per-
son years in 1981 to 17.6 in 1997. After the tipping point in 
1997, the ASR constantly decreased, reaching the lowest rate 
of 5.8/100 000 in 2014 (Figure 1). ASR were similar in males 
and females (Figure 1).
Mean survival time after diagnosis was 
12.3 ± 31.6 months (median 2.9). The average survival 
time after diagnosis has not improved from 1981 to 2014 
(Figure 2). However, there was an increase in CUP patients’ 
age from 70 years in 1981 to 80 years in 2014 (Figure 3). 
The mortality was significantly higher in patients with 
unclassified tumors and neoplasms (HR 1.25 [95% CI 
1.13- 1.66]) compared to adenocarcinomas. Squamous cell 
carcinomas (HR 0.48 [95% CI 0.41- 0.57]) and neuroendo-
crine carcinomas (HR 0.75 [95% CI 0.63- 0.88]) showed a 
significantly lower mortality compared to the adenocarci-
noma (Table 2). Patients under 60 years showed a signifi-
cantly lower mortality compared to patients with 60- 69 
(HR 1.45 [95% CI 1.27- 1.66]), 70- 79 (HR 1.60 [95% CI 
1.41- 1.81]) and above 80 years of age (HR 1.87 [95% CI 
1.65- 2.12]). Women had a lower mortality compared to 
men (HR 0.85 [95% CI 0.78- 0.92]). The above- identified 
factors are reflected in the Kaplan–Meier survival curves 
stratified by sex, age, and histological groups (Figure 4).
3.2 | Comprehensive genomic profiling and 
expression profiling
Several reviews address the potential of NGS.22-24 However, 
so far only 10 published studies documented the application 
of NGS on tissue or blood samples of CUP patients. Eight 
studies reported CGP of CUP patient cohorts with varying 
sizes (16- 1806 patients or samples), whereas two studies doc-
umented individual case reports (Table 3). Mutations with 
potential therapeutic relevance that could affect therapy se-
lection were identified in 30%- 85% of CUP patients, depend-
ing on the definition.12,13,25-27 In a recent study by Varghese 
et al27, who defined actionable alterations as biomarkers 
that are linked to a drug response either by FDA approval 
or other strong clinical evidence, targetable genomic altera-
tions were observed through CGP in 30% of the patients. In 
a study by Kato et al26, CGP allowed for identifying clini-
cally relevant genomic alterations potentially targetable by 
FDA- approved drugs in 63.8% of the patients, whereas 1.6% 
of the patients had alterations targetable with agents under 
investigation in clinical trials. This led to a total of 65% of 
the patients harboring potentially actionable alterations in the 
named study, which was the only one to use liquid biopsies 
for CGP of CUP syndromes.26 In a previous study by Ross 
et al13, as many as 85% of the patients had genomic altera-
tions that could potentially affect treatment decisions, but 
only for 13% of the patients these alterations were associ-
ated with approved targeted therapies. The remaining were 
linked to registered clinical trials and could enable patient 
entry into such.13 In all cases, neither immunohistochemistry, 
fluorescence in situ hybridization, serum biomarker analy-
sis nor mRNA transcriptional profiling had led to further 
insights.13 There were significant differences in the genetic 
profile of adenocarcinoma CUP compared to nonadenocarci-
noma CUP, suggesting differing targeted therapeutic strate-
gies for these different CUP types.13 In general, most CUP 
patients harbor unique molecular profiles.26,28 The results of 
Löffler et al29 identified genomic alterations in 84% of pa-
tients. About 15% of them included approved drugs. Gatalica 
et al25 used a multi- platform profiling (including immuno-
histochemistry, gene sequencing and in situ hybridization). 
Whereas this group identified only a limited number of ge-
netic mutations by CGP, various protein markers enabled the 
identification of druggable targets in 96% of the cases.25 A 
recent study selectively assessing predictive biomarkers for 
immune checkpoint inhibitors observed that 28% of the as-
sessed CUP patients would have been potentially eligible for 
such therapies.30 In addition to these larger cohorts of CUP 
patients, two case studies illustrated the potential benefit 
of CUP patients from targeted therapies after genetic test-
ing with immune checkpoint and mTOR inhibitors, respec-
tively31,32 (Table 3).
Our literature review also revealed 31 publications describ-
ing gene expression or epigenetic profiling in CUP patients 
using either PCR or microarray based assays (Table S1). Most 
studies aimed to demonstrate that gene expression profiling 
complements standard pathologic evaluation in determining 
the tissue of origin in CUP using commercially available or 
custom made assays.33-38 Sample size varied greatly from 16 
to 262 samples suitable for analysis per study.34,39 Success 
rate of commercialized assays identifying the tissue of ori-
gin ranged from 61% to 98%.38-41 The assay applied in the 
study with the lowest success rate of 61% identified the mo-
lecular profile of six tumor types based on 10 gene mark-
ers.40 On the other hand, in a study applying a commercially 
4 |   BINDER Et al.
Ta
bl
e 1
. 
Ch
ar
ac
ter
ist
ics
 an
d s
ur
vi
va
l t
im
e o
f C
UP
 pa
tie
nt
s i
n t
he
 ca
nt
on
 of
 Z
ur
ich
Al
l
Ad
en
oc
ar
cin
om
a
Sq
ua
m
ou
s C
ell
 
Ca
rc
in
om
a
Ne
ur
oe
nd
oc
rin
e  
ca
rc
in
om
a
Un
sp
ec
ifi
ed
  
ca
rc
in
om
as
Un
cla
ssi
fie
d  
ne
op
las
m
s
Pa
tie
nt
s
To
tal
N 
(%
)
29
35
 (1
00
.0)
12
41
 (4
2.3
)
19
3 (
6.6
)
18
8 (
6.4
)
48
8 (
16
.6)
82
5 (
28
.1)
M
en
N 
(%
)
13
80
 (4
7.0
)
53
8 (
43
.4)
12
9 (
66
.8)
10
8 (
57
.4)
25
9 (
53
.1)
34
6 (
41
.9)
W
om
en
N 
(%
)
15
55
 (5
3.0
)
70
3 (
56
.6)
64
 (3
3.2
)
80
 (4
2.6
)
22
9 (
46
.9)
47
9 (
58
.1)
Ag
e i
n y
ea
rs
To
tal
M
ea
n ±
 S
D
72
.9 
± 
12
.7
70
.7 
± 
12
.4
69
.3 
± 
13
.0
67
.5 
± 
13
.1
70
.1 
± 
12
.8
80
.0 
± 
9.9
M
ed
ian
75
.0
73
.0
69
.0
69
.0
72
.0
82
.0
M
en
M
ea
n ±
 S
D
71
.2 
± 
12
.3
69
.5 
± 
11
.4
68
.8 
± 
12
.4
66
.1 
± 
12
.7
68
.9 
± 
13
.1
77
.9 
± 
9.9
M
ed
ian
73
.0
71
.0
69
.0
68
.5
71
.0
80
.0
W
om
en
M
ea
n ±
 S
D
74
.5 
± 
12
.9
71
.6 
± 
13
.1
70
.3 
± 
14
.1
69
.4 
± 
13
.5
71
.6 
± 
12
.3
81
.5 
± 
9.5
M
ed
ian
77
.0
74
.0
69
.5
72
.0
73
.0
84
.0
Ag
e g
ro
up
s
<6
0
N 
(%
)
47
4 (
16
.1)
24
7 (
19
.9)
41
 (2
1.3
)
44
 (2
3.4
)
10
9 (
22
.3)
33
 (4
.0)
60
- 6
9
N 
(%
)
54
0 (
18
.4)
25
4 (
20
.5)
57
 (2
9.5
)
51
 (2
7.1
)
10
1 (
20
.7)
77
 (9
.4)
70
- 7
9
N 
(%
)
88
2 (
30
.1)
40
8 (
32
.8)
51
 (2
6.4
)
58
 (3
0.9
)
15
1 (
30
.9)
21
4 (
25
.9)
>8
0
N 
(%
)
10
39
 (3
5.4
)
33
2 (
26
.8)
44
 (2
2.8
)
35
 (1
8.6
)
12
7 (
26
.0)
50
1 (
60
.7)
M
on
th
s o
f 
Su
rv
iv
al
To
tal
M
ea
n ±
 S
D
12
.3 
± 
31
.6
10
.8 
± 
29
.2
31
.0 
± 
54
.5
19
.6 
± 
37
.2
13
.3 
± 
34
.5
6.7
 ±
 17
.6
M
ed
ian
 (Q
1-
 Q3
)
2.9
 (0
.9-
 9.0
)
3.0
 (1
.0-
 8.3
)
10
.1 
(3
.1-
 26
.5)
5.0
 (1
.5-
 21
.8)
3.4
 (1
.1-
 9.8
)
1.4
 (0
.5-
 4.5
)
M
en
M
ea
n ±
 S
D
11
.3 
± 
29
.1
9.3
 ±
 26
.1
22
.3 
± 
42
.2
21
.4 
± 
45
.3
12
.1 
± 
29
.0
6.1
 ±
 15
.6
M
ed
ian
 (Q
1-
 Q3
)
2.7
 (0
.9-
 8.3
)
2.6
 (0
.9-
 7.3
)
8.3
 (3
.1-
 22
.3)
3.7
 (1
.1-
 16
.8)
3.2
 (1
.2-
 9.7
)
1.3
 (0
.4-
 4.5
)
W
om
en
M
ea
n ±
 S
D
13
.1 
± 
33
.7
12
.0 
± 
31
.4
47
.8 
± 
69
.9
17
.5 
± 
23
.5
14
.7 
± 
39
.9
7.2
 ±
 19
.1
M
ed
ian
 (Q
1-
 Q3
)
3.0
 (0
.9-
 13
.1)
2.6
 (0
.9-
 7.3
)
16
.5 
(3
.7-
 53
.5)
3.7
 (1
.1-
 16
.8)
3.5
 (0
.9-
 10
.2)
1.4
 (0
.5-
 4.5
)
N 
= 
nu
m
be
r, 
% 
= 
in
 pe
rc
en
tag
e S
D 
= 
sta
nd
ar
d d
ev
iat
io
n, 
Q1
 =
 qu
ar
til
e 1
, Q
3 =
 qu
ar
til
e 3
.
   | 5BINDER Et al.
available 92- gene assay, 247 of 252 (98%) patients had a tis-
sue of origin predicted.39 A total of 194 patients then received 
assay- directed site- specific treatment subsequently leading to 
a median survival time of 12.5 months, which is favorable 
compared to previous results with empiric chemotherapy.39 
With a distinct assay quantitating 48 miRNAs, 62 of 74 cases 
(84%) the result was consistent with the clinicopathologic 
picture.35 In seven cases, a tissue of origin was predicted that 
was not classified with conventional diagnostics.35 Two stud-
ies performing epigenetic profiling with a DNA methylation 
microarray on CUP tissue samples, showed a prediction ac-
curacy of 78% and 87% for a primary tumor, respectively.42,43 
Furthermore, patients receiving subsequent tumor- specific 
therapy showed a threefold improved overall survival com-
pared to patients receiving empiric therapy.42 More details 
can be found in Table S1.
4 |  DISCUSSION
Our study shows a decreased incidence of CUP patients, 
whereas prognosis of patients with CUP has not improved 
in the last 30 years. In the period from 1981 to 2014, CUP 
patients account for 0.9%- 2.6% of all newly diagnosed cancer 
patients in Zurich. This is in line with earlier studies in other 
Swiss regions identifying CUPs as 2.3% of new cancer diag-
noses.5 CUPs account also for 2% of all new cancer diagno-
ses in the US,5,16 but are about 4% in the Netherlands, South 
Australia, and Scotland.4,5,16,23,44 Differences between coun-
tries may be explained by different coding rules in cancer 
registries or different clinical or diagnostic procedures. In ad-
dition, reimbursement in the United States is more favorable 
for specific cancers compared to CUP. This could indirectly 
influence the classification of CUP cases as a specific cancer 
Figure 1. Age- standardized incident rates of CUP in the canton of Zurich 1981- 2014. A, Overall, B, by morphology, C, by age group
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based on the physician’s best guess may be chosen, lead-
ing to an underestimation of CUP incidence.17 With 28.1%, 
we report a substantially higher percentage of unclassified 
neoplasms/tumors, whereas 16.6% unspecified carcinomas is 
much lower than expected according to a recently published 
classification.1 This may also be due to coding methodology 
with some unspecified carcinomas being declared as unclas-
sified neoplasms/tumors.
ASR increased to a high in 1997 and significantly de-
creased thereafter. The higher ASR between 1981 and 
1997 may be due to increased CUP awareness and more 
frequent use of imaging technologies. The subsequent de-
crease in ASR may be due to better imaging technologies 
including computer tomography, broader use of endos-
copy, and better immunohistochemical tools in pathology, 
which has led to a significant reduction in diagnostic er-
rors in general.45,46 Hence, also a higher identification rate 
of primary tumors may be assumed. In this time period, 
extensive immunohistochemical antibody panels have been 
introduced, including estrogen and progesterone receptors, 
neuroendocrine markers, different cytokeratins, as well 
as group- or organ- specific tumor markers, for example, 
prostate (PSA), breast (NYBR1), lung/thyroid (TTF1), 
and renal cancer- specific markers (RCC).47 However, 
it is estimated that immunohistochemistry helps to pin-
point the tissue of origin in less than 30% of CUP cases.48 
Comparable time trends with a peak in the late 1990s have 
been observed in the Swedish, Scottish, and Australian pop-
ulation.6,19,44 In the Norwegian, Finnish, and US popula-
tion, the tipping point was before 1990,6,16,17 which may 
be due to an earlier use of more aggressive diagnostics. In 
Scotland and Australia, ASR comparable with Switzerland 
have been documented.5,19 For the US, however, lower 
ASR of 4- 6.6/100 000 person years have been reported, 
whereas Sweden reported ASR of 6/100 000 with the peak 
at 8/100 000 person years.6,16,17
Figure 2. Mean survival in days of CUP patients in the canton of Zurich 1981- 2014. A, Overall, B, by morphology, C, by age group
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Overall survival of CUP patients in Zurich has not im-
proved over the last 34 years, which is similar to Sweden and 
the United States.16,20 One reason for this limited treatment 
success could be the higher patient age at diagnosis in the last 
years. Whether the prognosis is worse for CUP compared to 
metastatic cancers of known primary depends on the sites of 
the primary tumors and the metastasis.49 Patient management 
and overall survival have improved significantly over the last 
decades for some metastatic cancers such as ovarian, colorec-
tal, and breast cancer.20,50 In contrast, improved survival has 
been limited to specific locations of CUP such as peritoneum, 
pelvis, and nervous system.20 We observed a better prognosis 
for CUP with squamous cell and neuroendocrine carcinoma 
CUP compared to adenocarcinomas. This is in line with re-
cent reports about a slightly improved prognosis of CUP pa-
tients with squamous cell carcinoma, which may partly be 
due to aggressive treatment of nodal positive squamous cell 
carcinoma.20,50
The lack of any treatment progress in patients with CUP 
led us to perform a literature review on novel diagnostic tools. 
To date, CUPs are mainly investigated by immunohistochem-
istry. Recently, gene expression arrays have been added to the 
diagnostic armamentarium, while the use of next- generation 
gene sequencing for CGP to search for therapeutic targets has 
just begun.13,22,26 According to our literature search, gene 
expression profiling could complement standard pathologic 
diagnostic workup in determining the organ of origin in pa-
tients with CUP, particularly when immunohistochemistry 
is inconclusive.24,36,38 However, the added value of gene ex-
pression analyses varies, because the accuracy of the identi-
fication of the tissue of origin by gene expression profiling 
Figure 3. Mean age at diagnosis for CUP patients in the canton of Zurich 1981- 2014. A, Overall, B, by morphology
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Table 2. Mortality of CUP patients adjusted for sex, age and 
histological groups
HR Lower CI Upper CI
Sex
 Male 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 Female 0.85 0.78 0.92
Histology
 Adenocarcinoma 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 Squamous cell 
carcinoma
0.48 0.41 0.57
 Neuroendocrine 
carcinoma
0.75 0.63 0.88
 Unspecified/undifferen-
tiated carcinomas
0.90 0.81 1.01
 Unclassified neoplasms/
tumors
1.25 1.13 1.66
Age
 <60 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 60- 69 1.45 1.27 1.66
 70- 79 1.60 1.41 1.81
 >80 1.87 1.65 2.12
HR, hazard ratio; CI, 95% confidence interval.
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depends on the sample quality compared to blood- based 
CGP.37 Hence, in certain clinical situations samples may not 
meet quality control criteria for the test and tissues might be 
misclassified.37,38,51 The success rate of the test also depends 
on the number of tissues covered by the test and its robust-
ness. One study showed that a commercial assay covering six 
tumor types, only identified the tissue of origin of 63 of 104 
patients as for 41 patients, the molecular profiles were not 
specific for the tissue types detectable by the assay.40 There 
is currently no gold standard to assess gene expression profil-
ing tests, and most of the sample sizes are still fairly small.52 
Nevertheless, gene expression profiles are considered a valu-
able addition to the standard diagnostic approach to identify 
the tumor of origin.52 Epigenetic profiles may add an addi-
tional piece to the puzzle of identifying the molecular profile 
of CUP patients.53 By assessing the DNA methylation profile 
of CUP patients, 78%- 87% of the primary tumor were identi-
fied.42,43 An advantage of this approach over gene expression 
profiling is the use of DNA, a material stable over time, and 
less reactive to external factors compared to RNA.42
However, CUP can harbor genetic traits distinct from tu-
mors of known primaries that may be clinically relevant.54,55 
They do not simply lack a few key markers of differentiation, 
but rather have fundamentally distinct gene expression pat-
terns.54,55 The incidence of mutations in the MET oncogene, 
for example, was significantly higher in CUP than in tumors 
of known origin.56
All CGP studies identified in our literature research iden-
tified clinically relevant genomic alterations using panels of 
47- 701 genes.12,13,26-30 These are strong indications that po-
tentially actionable genetic alterations are present in CUPs. 
However, it is no surprise that the rate of clinically relevant 
mutations in CUPs is strongly dependent on (a) the definition 
of what is to be considered a clinically actionable alteration 
and (b) panel type and size. Five of the eight studies identi-
fied such mutations with NGS technologies in >65% of the 
samples, which in 13%- 64% of the cases may be targeted 
with currently approved therapies (off- label).12,13,26,29 Other 
mutations could allow for including patients into ongoing 
clinical trials.12,13,26 A recent study defining actionable al-
terations rather narrowly as biomarkers that are linked to a 
drug response either by FDA approval or other strong clin-
ical evidence, identified targetable genomic alterations by 
CGP in 30% of the patients.27 However, if genetic alterations, 
for which preclinical evidence for a specific drug response 
exists, are included, additional genomic alterations were ob-
served in another 38 of the 150 patients leading to a total of 
55% with potentially targetable mutations.27 If only biomark-
ers for immune checkpoint inhibitors were assessed, relevant 
mutations were found in 28% of the patients.30 Another study 
reporting lower mutation rates in CUP patients, applied a 
panel consisting of as little as 47 genes; hence, in the end, 
most druggable targets were identified by conventional im-
munohistochemistry and CGP only refined some diagno-
ses.25 However, more recent studies applying panels of 50- 70 
genes have also detected mutations in >80% of the investi-
gated cases.26,29 Hence, panel selection rather than panel size 
seems to influence the amount of targetable mutations de-
tected and the contribution of CGP to the diagnostic workup 
of CUP patients.
Given poor prognosis and limited treatment options for 
patients with CUP, genomic profiling using NGS technolo-
gies may meet a clinical need. A large number of CUP pa-
tients could benefit from molecularly targeted therapies, 
because clinically relevant mutations are observed in 30%- 
85% of the CUP patients. Treatment based on the site of 
Figure 4. Kaplan–Meier survival curves for death in CUP patients depending on sex, age and morphology A, overall, B, by age group, C, by 
morphology with 1: adenocarcinomas, 2: squamous cell carcinomas, 3: neuroendocrine carcinomas, 4: unspecified/undifferentiated carcinomas, 5: 
unclassified neoplasms/tumors
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origin may be increasingly replaced by a treatment based on 
the molecular signature of the cancer leading to more precise 
and effective therapy.54,55,57,58 Furthermore, dynamic change 
in the genomic profile of the tumor can be monitored and the 
treatment adapted accordingly.26
5 |  CONCLUSION
CUP remains an important clinical problem given frequency, 
outcome, and progress in a chemoresistant fashion. This study 
shows that the overall survival of CUP patients has not im-
proved since the early 1980s. The reduced costs of NGS test-
ing in the future and potential use of targeting agents for CUP 
could lead to increasing use of NGS, particularly if identifica-
tion of the primary site becomes less relevant than the molecu-
lar signature of a CUP. Further development of personalized 
oncology for CUP will require clinical trials based on CGP.
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